Key result
Systemic lupus erythematosus was associated with a non-significant increase in metabolic syndrome compared with matched controls.
Why the study?
Is metabolic syndrome more frequent in patients with systemic lupus erythematosus compared to matched controls, and is it associated with cardiovascular disease?
Cross-Sectional (n=405)
Is metabolic syndrome more frequent in patients with systemic lupus erythematosus compared to matched controls, and is it associated with cardiovascular disease?
Patients with SLE, particularly those under 40, have a higher prevalence of metabolic syndrome and a markedly increased risk of cardiovascular disease compared to matched controls.
Answers are grounded in this paper and cite their sources.
Non-significant metabolic syndrome trend in SLE warrants no practice change; leaves open its contribution to excess cardiovascular risk.
The aim of this cross-sectional study was to establish the frequency, phenotype and characteristics of metabolic syndrome (MS), as defined by the Adult Treatment Panel III, in a cohort of patients with systemic lupus erythematosus (SLE) and its possible association with cardiovascular diseases (CVD). A total of 160 patients with SLE and 245 age, sex, educational level and ethnically matched controls were included. Association with cardiovascular risk factors, SLE features, treatment of SLE and history of CVD were assessed in patients with SLE and controls with and without MS. MS was non-significantly increased in patients with SLE (20%) compared with controls (13%; P = 0.083). It was more commonly observed in patients with SLE < or =40 years old (15.8%) than in controls of the same age group (4.2%; P < 0.001). The mean number of MS criteria was significantly higher among patients with SLE than in controls. The frequency of CVD was also 28-fold higher among patients with SLE (11.3%) than in controls (0.4%). SLE with MS presented higher levels of inflammatory markers than SLE without MS. In a multivariate analysis, educational level, serum triglycerides, HDL-cholesterol and C3 serum levels and hydroxychloroquine use were independently associated with MS.
No takes yet. Share an insight, caveat, or question.
Sabio et al. (2008) conducted a cross-sectional in Systemic lupus erythematosus (SLE) (n=405). Systemic lupus erythematosus vs. Matched controls was evaluated on Metabolic syndrome (p=0.083). Systemic lupus erythematosus was associated with a non-significant increase in metabolic syndrome compared with matched controls.
Synapse has enriched 10 related papers. Consider them for comparative context: